Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

NCT05084963
completedphase_1

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

NCT05921591
completedphase_2

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

NCT05098522
completedphase_1

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

NCT04748536

Clinical Trials (4)

Showing 4 of 4 trials
NCT05084963Phase 2

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Completed
NCT05921591Phase 1

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Completed
NCT05098522Phase 2

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

Completed
NCT04748536Phase 1

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4